Clinical Trial Update: Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk [Phase 2, Phase 3]

View source ↗

Summary

This Clinical Trial Update notes a Phase 2/3 study evaluating whether clopidogrel can prevent the development of systemic sclerosis, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Scleroderma, Systemic Sclerosis | Phase 2, Phase 3 | Status: RECRUITING